Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Expenses:
Research and development	$ 1,499	$ 2,038
General and administrative	2,558	2,554
Total operating expenses	4,057	4,592
Operating loss	(4,057)	(4,592)
Other income:
Investment income, net	71	227
Total other income	71	227
Net loss	(3,986)	(4,365)
Less - net income attributable to noncontrolling interests	4	2
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (3,990)	$ (4,367)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.38)	$ (0.44)
Weighted average common shares outstanding
Basic and diluted shares	10,623	10,027